An observational study in Coronary Artery Disease and Atrial Fibrillation, sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by China National Center for Cardiovascular Diseases · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Coronary Artery Disease by China National Center for Cardiovascular Diseases — 26 open to participants now, 27 under way, none of them phase 3. Coronary Artery Disease · China National Center for Cardiovascular Diseases.
Among the 57 studies in Coronary Artery Disease by China National Center for Cardiovascular Diseases, this one is the 14th largest by planned enrollment of the 25 observational ones that give a count, is one of 10 that started in 2025, is one of 25 observational ones, reaches primary completion later than 12 of the 26 other live ones, and was the 42nd registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →26 of the 57 studies in Coronary Artery Disease by China National Center for Cardiovascular Diseases are open now, in 1 country. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+ · Healthy volunteers
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–75
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 430 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 501 across the 32 interventional studies, 460 across the 25 observational. Of the 20 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
China National Center for Cardiovascular Diseases is the lead sponsor of 271 studies on the registry; 143 are open to participants now.
6 of the studies in Coronary Artery Disease by China National Center for Cardiovascular Diseases that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05638867China National Center for Cardiovascular DiseasesNOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI | 2026-12 |
| NCT06917664China National Center for Cardiovascular DiseasesTreatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease | 2026-12 |
| NCT07660419China National Center for Cardiovascular DiseasesEffect of Mobile-Based Home Cardiac Rehabilitation on Coronary Plaque | 2026-12-31 |
| NCT06822894China National Center for Cardiovascular DiseasesClinical Implications of Three-vessel Ultrasonic Flow Ratio Measurement in Patients With Coronary Artery Disease | 2026-12-31 |
| NCT06932874China National Center for Cardiovascular DiseasesMetformin Hydrochloride Sustained-release Tablets (Ⅲ) in Patients With Type 2 Diabetes Mellitus Complicated With Coronary Heart Disease | 2026-12-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 57 studies in Coronary Artery Disease by China National Center for Cardiovascular Diseases, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will include the subjects who enrolled in pCAD-POAF trial (NCT05009914) to observe clinical outcomes 3 years after surgery.
The primary outcome is the time to first occurrence of a composite of all-cause death, stroke, systemic embolism, myocardial infarction, unplanned cardiac rehospitalization, or post-discharge atrial fibrillation from randomization through 3 years after surgery.
The secondary outcomes are:the individual components of the primary composite outcome; unplanned all-cause rehospitalization; arrhythmias other than atrial fibrillation; premature atrial contraction and premature ventricular contraction burdens; heart rate variability parameters; quality-of-life scores; and other Holter-derived parameters.
This study aimed to observe clinical outcomes 3 years after surgery in patients enrolled in pCAD-POAF trial.
After completing the pCAD-POAF trial, investigators would not make any other interventions on enrolled patients. At the 3 year follow-up visit, all subjects will undergo regular laboratory test , electrocardiogram (ECG), ultrasound cardiography (UCG). Besides, coronary computed tomographic angiography(CCTA) will be performed depending on their own willingness. In the meantime, all subjects will be continuously monitored by wearing specific device for the detection of arrhythmias. Data collection will also include the use of medications, medical tests, any documented arrhythmias and the occurrence of clinical events within the 3 years.
In conclusion, this is a extensive follow-up of previous RCT and a non-interventional, observational study.
The population enrolled previously in pCAD-POAF trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This group underwent partial cardiac denervation procedure as well as CABG in the pCAD-POAF trial. However, no other intervention was performed after completing the pCAD-POAF trial.
Other: no other intervention
This group only underwent CABG in the pCAD-POAF trial. Likewise, no other intervention was performed after completing the pCAD-POAF trial
Other: no other intervention
This is a observational study.
A composite of all-cause death, stroke, systemic embolism, myocardial infarction, unplanned cardiac rehospitalization, or post-discharge atrial fibrillation.
The primary outcome was the time to first occurrence of a composite of all-cause death, stroke, systemic embolism, myocardial infarction, unplanned cardiac rehospitalization, or post-discharge atrial fibrillation from randomization through 3 years after surgery.
Time frame: 3 year after the surgery
the individual components of the primary composite outcome
the individual components of all-cause death, stroke, systemic embolism, myocardial infarction, unplanned cardiac rehospitalization, or post-discharge atrial fibrillation
Time frame: within 3 year after surgery
unplanned all-cause rehospitalization
unplanned all-cause rehospitalization
Time frame: within 3 year after surgery
premature atrial contraction and premature ventricular contraction burdens
premature atrial contraction and premature ventricular contraction burdens recorded by the 3-day continuous ECG monitoring
Time frame: 3 year after surgery
Holter-derived parameter, mean heart rate
mean heart rate derived from the 3-day ECG monitoring
Time frame: 3 year after the surgery
Holter-derived parameter, HRV
HRV derived from the 3-day ECG monitoring
Time frame: 3 year after the surgery
Assessment of quality of life
Assessed by EQ-5D-5L (EuroQol 5-Dimensions 5-Levels questionnaire, higher score means better outcome) and AFEQT (Atrial-Fibrillation-Effect-on-Quality-of-life-Questionnaire, higher score means better outcome).
Time frame: 3 year after the surgery
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Jan 2027, 17 months after the start.
Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 17 months is below that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China National Center for Cardiovascular Diseases →